244 related articles for article (PubMed ID: 34215687)
21. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Zhu C; Song Z; Wang A; Srinivasan S; Yang G; Greco R; Theilhaber J; Shehu E; Wu L; Yang ZY; Passe-Coutrin W; Fournier A; Tai YT; Anderson KC; Wiederschain D; Bahjat K; Adrián FJ; Chiron M
Front Immunol; 2020; 11():1771. PubMed ID: 32922390
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P
Haematologica; 2020 Apr; 105(4):1032-1041. PubMed ID: 31296574
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma.
Vockova P; Svaton M; Karolova J; Pokorna E; Vokurka M; Klener P
Folia Biol (Praha); 2020; 66(1):17-23. PubMed ID: 32512655
[TBL] [Abstract][Full Text] [Related]
25. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study.
Huang H; Zhu J; Yao M; Kim TM; Yoon DH; Cho SG; Eom HS; Lim ST; Yeh SP; Song Y; Kwong YL; Kim JS; Jin J; Shi Y; Kim H; Qing M; Zhou T; Gao G; Dong Z; Qi M; Kim WS
J Hematol Oncol; 2021 Feb; 14(1):25. PubMed ID: 33588922
[TBL] [Abstract][Full Text] [Related]
28. The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.
Matas-Céspedes A; Vidal-Crespo A; Rodriguez V; Villamor N; Delgado J; Giné E; Roca-Ho H; Menéndez P; Campo E; López-Guillermo A; Colomer D; Roué G; Wiestner A; Parren PW; Doshi P; van Bueren JL; Pérez-Galán P
Clin Cancer Res; 2017 Mar; 23(6):1493-1505. PubMed ID: 27637890
[No Abstract] [Full Text] [Related]
29. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
30. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
31. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.
Brennan K; Iversen KF; Blanco-Fernández A; Lund T; Plesner T; Mc Gee MM
Cells; 2022 Oct; 11(21):. PubMed ID: 36359760
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
33. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Siddiqui BA; Chapin BF; Jindal S; Duan F; Basu S; Yadav SS; Gu AD; Espejo AB; Kinder M; Pettaway CA; Ward JF; Tidwell RSS; Troncoso P; Corn PG; Logothetis CJ; Knoblauch R; Hutnick N; Gottardis M; Drake CG; Sharma P; Subudhi SK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948506
[TBL] [Abstract][Full Text] [Related]
34. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
35. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab-
Dawicki W; Allen KJH; Jiao R; Malo ME; Helal M; Berger MS; Ludwig DL; Dadachova E
Oncoimmunology; 2019; 8(8):1607673. PubMed ID: 31413916
[TBL] [Abstract][Full Text] [Related]
37. Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity.
Yu T; Qiao C; Lv M; Tang L
BMC Biotechnol; 2019 May; 19(1):28. PubMed ID: 31118070
[TBL] [Abstract][Full Text] [Related]
38. Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.
Lejeune M; Duray E; Peipp M; Clémenceau B; Baron F; Beguin Y; Caers J
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203012
[TBL] [Abstract][Full Text] [Related]
39. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Casneuf T; Xu XS; Adams HC; Axel AE; Chiu C; Khan I; Ahmadi T; Yan X; Lonial S; Plesner T; Lokhorst HM; van de Donk NWCJ; Clemens PL; Sasser AK
Blood Adv; 2017 Oct; 1(23):2105-2114. PubMed ID: 29296857
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase.
Gao T; Huang J; Yin H; Huang J; Xie J; Zhou T; Fan W; Yang X; Gao G; Li Z
Cell Death Dis; 2023 May; 14(5):316. PubMed ID: 37160920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
